ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Arcus Biosciences, Gilead Sciences and Otsuka side by side

Their registered studies and the programs behind them, as ClinicalTrials.gov shows them and the companies' own pipelines name them. Counts, not rankings: the companies differ in size, so each number is shown beside its share of that company's own programs.

Arcus Biosciences×Gilead Sciences×Otsuka×Three at a time for now; Pro will compare up to ten.

At a glance

Studies each sponsor leads, with the companies grouped under it. Every number opens the studies it counts.

Arcus BiosciencesGilead SciencesOtsuka
studies on the registry32739784
open to participants now43356
phase 3 studies under way23331
reach primary completion within a year31923
programswith a study of their own in two years33225

Pipeline by phase

Each program once, at the furthest phase its own studies reached. The bar is the share of that company's programs, so a small company and a large one read on the same scale.

Furthest phaseArcus BiosciencesGilead SciencesOtsuka
Phase 1

Arcus Biosciences: 1 of its 3 programs at phase 1

  1. AB102phase 1
33%

Gilead Sciences: 6 of its 32 programs at phase 1

  1. GS-0151phase 1
  2. GS-0415phase 1
  3. GS-1206phase 1
  4. GS-2426phase 1
  5. GS-5319phase 1

and 1 more — sign in to see them all

19%

Otsuka: 12 of its 25 programs at phase 1

  1. VIS171phase 1
  2. 1-(12-(1 CARBOXYCYCLOPROPYL)DODECYL)CYCLOPROPANE-1-CARBOXYLIC acidphase 1
  3. ARC-02phase 1
  4. HBM7020phase 1
  5. SEP-380135phase 1

and 7 more — sign in to see them all

48%
Phase 200%

Gilead Sciences: 6 of its 32 programs at phase 2

  1. Autologous Anti-CD19/CD20 CAR-T Cells KITE-363phase 2
  2. denikitugphase 2
  3. GS-1179phase 2
  4. GS-4321phase 2
  5. PTM Cilofexor Dose Aphase 2

and 1 more — sign in to see them all

19%

Otsuka: 2 of its 25 programs at phase 2

  1. VIS954phase 2
  2. OPC 131461phase 2
8%
Phase 3

Arcus Biosciences: 2 of its 3 programs at phase 3

  1. casdatifanphase 3
  2. quemliclustatphase 3
67%

Gilead Sciences: 15 of its 32 programs at phase 3

  1. anitocabtagene autoleucelphase 3
  2. domvanalimabphase 3
  3. seladelparphase 3
  4. axicabtagene ciloleucelphase 3
  5. GS-3242phase 3

and 10 more — sign in to see them all

47%

Otsuka: 10 of its 25 programs at phase 3

  1. sibeprenlimabphase 3
  2. ulotarontphase 3
  3. centanafadine hydrochloridephase 3
  4. futibatinibphase 3
  5. repinatrabitphase 3

and 5 more — sign in to see them all

40%
Approved, new studies00%

Gilead Sciences: 5 of its 32 programs at approved, new studies

  1. sacituzumab govitecanapproved, new study
  2. lenacapavirapproved, new study
  3. tenofovir alafenamideapproved, new study
  4. bictegravirapproved, new study
  5. Emtricitabineapproved, new study
16%

Otsuka: 1 of its 25 programs at approved, new studies

  1. Tolvaptanapproved, new study
4%

Readouts ahead

Programs whose next study reaches primary completion in each month, by the sponsor's own estimate. A ring marks a month with a phase 3 readout.

Nov ’26DecJan ’27FebMarAprMayJunJulAugSepOct
Arcus Biosciences2 readouts · 0 phase 3·

Arcus Biosciences, Dec ’26: 1 program whose next study reaches primary completion

  1. AB102phase 1 · Dec 0 · NCT07662057
····

Arcus Biosciences, May ’27: 1 program whose next study reaches primary completion

  1. casdatifanphase 3 · May 0 · NCT07751250
·····
Gilead Sciences10 readouts · 2 phase 3·

Gilead Sciences, Dec ’26: 2 programs whose next study reaches primary completion

  1. anitocabtagene autoleucelphase 3 · Dec 0 · NCT05396885
  2. sacituzumab govitecanapproved, new study · Dec 0 · NCT04617522
··

Gilead Sciences, Mar ’27: 4 programs whose next study reaches primary completion

  1. domvanalimabphase 3 · Mar 0 · NCT06727565
  2. GS-0151phase 1 · Mar 0 · NCT06902519
  3. lenacapavirapproved, new study · Mar 0 · NCT06749054
  4. Optimized Background Regimen (OBR)phase 3 · Mar 0 · NCT06749054
··

Gilead Sciences, Jun ’27: 2 programs whose next study reaches primary completion, 2 in phase 3

  1. Emtricitabineapproved, new study · Jun 0 · NCT06337032
  2. tenofovir alafenamideapproved, new study · Jun 0 · NCT06337032
·

Gilead Sciences, Aug ’27: 2 programs whose next study reaches primary completion

  1. bictegravirapproved, new study · Aug 0 · NCT07645287
  2. GS-3242phase 3 · Aug 0 · NCT07645287
··
Otsuka8 readouts · 3 phase 3·

Otsuka, Dec ’26: 2 programs whose next study reaches primary completion, 1 in phase 3

  1. difamilastphase 3 · Dec 0 · NCT07173478
  2. futibatinibphase 3 · Dec 0 · NCT05727176
·

Otsuka, Feb ’27: 1 program whose next study reaches primary completion

  1. repinatrabitphase 3 · Feb 9 · NCT07713758

Otsuka, Mar ’27: 1 program whose next study reaches primary completion

  1. sibeprenlimabphase 3 · Mar 13 · NCT06928142
·

Otsuka, May ’27: 2 programs whose next study reaches primary completion, 2 in phase 3

  1. centanafadine hydrochloridephase 3 · May 27 · NCT07759154
  2. zipalertinibphase 3 · May 27 · NCT05973773

Otsuka, Jun ’27: 1 program whose next study reaches primary completion

  1. zimberelimabphase 3 · Jun 0 · NCT04999761
·

Otsuka, Aug ’27: 1 program whose next study reaches primary completion

  1. 1-(12-(1 CARBOXYCYCLOPROPYL)DODECYL)CYCLOPROPANE-1-CARBOXYLIC acidphase 1 · Aug 25 · NCT07525960
··
size: programs that monthincludes phase 3Dates are estimates the sponsors file and often move.

Changed in the last 90 days

Since Aug 22, 2026: programs whose first study was registered, programs that reached a new phase, studies stopped, and primary completions moved later (a month or more in phase 3, three otherwise). Stops and dates are read from the registry’s changes, kept since Sep 25, 2026.

Arcus Biosciences

New programs 0

None

Reached a new phase 0

None

Study stopped 0

None

Primary completion later 0

None

Gilead Sciences

New programs 2

Reached a new phase 0

None

Study stopped 0

None

Primary completion later 6

Otsuka

New programs 0

None

Reached a new phase 1

  • VIS954phase 2 · Oct 23 · Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis

Study stopped 1

  • SEP-380135phase 1 · withdrawn Nov 19 · none of its studies left running“The trial was withdrawn prior to participant enrollment.” · NCT07455084

Primary completion later 3

Where they overlap

Conditions where at least two of them have programs: 8 in all. A program counts in each condition its studies name most.

ConditionArcus BiosciencesGilead SciencesOtsuka
Carcinoma, Non-Small-Cell Lungall three · compare here

Arcus Biosciences in Carcinoma, Non-Small-Cell Lung: 1 program

  1. quemliclustatphase 3

Their studies: Arcus Biosciences’ studies of Carcinoma, Non-Small-Cell Lung in search

Gilead Sciences in Carcinoma, Non-Small-Cell Lung: 3 programs

  1. domvanalimabphase 3
  2. Topotecanphase 3
  3. sacituzumab govitecanapproved, new study

Their studies: Gilead Sciences’ studies of Carcinoma, Non-Small-Cell Lung in search

Otsuka in Carcinoma, Non-Small-Cell Lung: 2 programs

  1. zipalertinibphase 3
  2. zimberelimabphase 3

Their studies: Otsuka’s studies of Carcinoma, Non-Small-Cell Lung in search

Adenocarcinoma Of Esophagusall three · compare here

Arcus Biosciences in Adenocarcinoma Of Esophagus: 1 program

  1. quemliclustatphase 3

Their studies: Arcus Biosciences’ studies of Adenocarcinoma Of Esophagus in search

Gilead Sciences in Adenocarcinoma Of Esophagus: 2 programs

  1. domvanalimabphase 3
  2. denikitugphase 2

Their studies: Gilead Sciences’ studies of Adenocarcinoma Of Esophagus in search

Otsuka in Adenocarcinoma Of Esophagus: 2 programs

  1. futibatinibphase 3
  2. zimberelimabphase 3

Their studies: Otsuka’s studies of Adenocarcinoma Of Esophagus in search

Breast Neoplasms2 of 3 · compare here–

Gilead Sciences in Breast Neoplasms: 4 programs

  1. amrubicinphase 3
  2. lurbinectedinphase 3
  3. trifluridine tipiracil drug combinationphase 2
  4. sacituzumab govitecanapproved, new study

Their studies: Gilead Sciences’ studies of Breast Neoplasms in search

Otsuka in Breast Neoplasms: 1 program

  1. futibatinibphase 3

Their studies: Otsuka’s studies of Breast Neoplasms in search

Lymphoma, B-Cell2 of 3 · compare here–

Otsuka in Lymphoma, B-Cell: 1 program

  1. ARC-02phase 1

Their studies: Otsuka’s studies of Lymphoma, B-Cell in search

Kidney Failure, Chronic2 of 3 · compare here–

Gilead Sciences in Kidney Failure, Chronic: 2 programs

  1. bictegravirapproved, new study
  2. Emtricitabineapproved, new study

Their studies: Gilead Sciences’ studies of Kidney Failure, Chronic in search

Otsuka in Kidney Failure, Chronic: 1 program

  1. Tolvaptanapproved, new study

Their studies: Otsuka’s studies of Kidney Failure, Chronic in search

Neoplasm Metastasis2 of 3 · compare here–

Gilead Sciences in Neoplasm Metastasis: 1 program

  1. sacituzumab govitecanapproved, new study

Their studies: Gilead Sciences’ studies of Neoplasm Metastasis in search

Otsuka in Neoplasm Metastasis: 2 programs

  1. futibatinibphase 3
  2. zimberelimabphase 3

Their studies: Otsuka’s studies of Neoplasm Metastasis in search

Arthritis, Rheumatoid2 of 3 · compare here–

Gilead Sciences in Arthritis, Rheumatoid: 1 program

  1. GS-0151phase 1

Their studies: Gilead Sciences’ studies of Arthritis, Rheumatoid in search

Otsuka in Arthritis, Rheumatoid: 1 program

  1. HBM7020phase 1

Their studies: Otsuka’s studies of Arthritis, Rheumatoid in search

Lung Neoplasms2 of 3 · compare here–

Gilead Sciences in Lung Neoplasms: 1 program

  1. amrubicinphase 3

Their studies: Gilead Sciences’ studies of Lung Neoplasms in search

Otsuka in Lung Neoplasms: 1 program

  1. zipalertinibphase 3

Their studies: Otsuka’s studies of Lung Neoplasms in search

Same targetBetaPro · free during the beta

Programs that act on the same gene, from the company’s own words, a judged reading of NCIt, ChEMBL or the studies, or a rule. A reading by rule is marked rule.

No gene two of them both target, among the programs whose target is known.

A target, or a pathogen for a vaccine, known for: Arcus Biosciences 2 of 3 · Gilead Sciences 16 of 32 · Otsuka 7 of 25 programs (20 of them by rule). Most early programs are named only by a code and their companies do not say what they act on, so this list is short and grows as targets are read.

What this can't show

  • Only what ClinicalTrials.gov holds: programs run only in other registries are missing.
  • Grouping is ours: subsidiaries and acquisitions counted under the parent, each dated and sourced on the sponsor page.
  • Readout dates are the sponsors’ estimates, not results.
  • A program is a drug as the registry names it: a code its company has not tied to a name counts on its own until it is read, and a study run under a partner’s name counts for the partner.
  • “Same target” covers only the programs whose target is known, from the company’s words, a judged reading or a rule; most early programs say nothing of it.